Clinical Research Directory

REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

Sponsor: Regeneron Pharmaceuticals

Summary

This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten worse or has not responded to previous treatment. The study is looking at: * What side effects REGN9220 might cause when given with odronextamab * How well REGN9220 works when given with odronextamab * How much REGN9220 is in the blood at different times when given with odronextamab * If the body makes antibodies to REGN9220 when given with odronextamab, this may cause the REGN9220 to not work as well * How the body and immune system changes after having REGN9220 given with odronextamab, which can help researchers understand why REGN9220 given with odronextamab works better in some people than others * What is the best dose of REGN9220 when given with odronextamab

Official title: Phase 1 Trial to Investigate the Safety and Tolerability of REGN9220, an Anti-CD22 X Anti-4-1BB Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Key Details

Conditions

Interventions